Also trades as: AUP.TO (TSX) · $vol 4M
AUPH NASDAQ
Aurinia Pharmaceuticals Inc.
1W: -2.5%
1M: -5.9%
3M: +7.3%
YTD: +0.7%
1Y: +86.1%
3Y: +51.3%
5Y: +29.6%
$15.22
-0.23 (-1.49%)
After Hours: $15.32 (+0.10, +0.69%)
Weekly Expected Move ±6.0%
$13
$14
$15
$16
$17
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$283M
+20.4% ▲
5Y CAGR: +41.4%
Gross Profit
$250M
+21.0% ▲
5Y CAGR: +38.0%
Operating Income
$105M
+2338.4% ▲
Net Income
$287M
+4893.1% ▲
EPS (Diluted)
$2.07
+5167.2% ▲
EBITDA
$128M
+302.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $46M | $134M | $176M | $235M | $283M |
| YoY Growth | -9.0% | +193.9% | +31.0% | +34.0% | +20.4% |
| Cost of Revenue | $1M | $6M | $14M | $28M | $33M |
| Gross Profit | $45M | $128M | $161M | $207M | $250M |
| Gross Margin | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| R&D Expenses | $51M | $45M | $50M | $21M | $33M |
| SG&A Expenses | $171M | $196M | $195M | $172M | $102M |
| Operating Expenses | $225M | $240M | $253M | $212M | $145M |
| Operating Income | -$181M | -$111M | -$92M | -$5M | $105M |
| Operating Margin | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
| Interest Expense | $0 | $0 | $3M | $5M | $4M |
| Income Before Tax | -$180M | -$106M | -$77M | $7M | $114M |
| Tax Expense | $760K | $2M | $551K | $2M | -$173M |
| Net Income | -$181M | -$108M | -$78M | $6M | $287M |
| Net Margin | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
| EPS (Diluted) | $-1.40 | $-0.76 | $-0.54 | $0.04 | $2.07 |
| EBITDA | -$177M | -$104M | -$63M | $32M | $128M |
| Shares Outstanding | 129M | 142M | 143M | 146M | 139M |